8-K: Milestone Scientific Receives $1.98 Million from Sale of Tax Benefits

Milestone Scientific received $1.98 million from Comcast Corporation through the sale of its unused tax benefits under the New Jersey Emerging Technology and Biotechnology Financial Assistance Program.

Summary

• Milestone Scientific was approved to participate in the New Jersey Emerging Technology and Biotechnology Financial Assistance Program on September 12, 2023.
• This program allows companies to transfer unused Net Operating Loss (NOL) Carryover and Research and Development (R&D) Tax Credits for value.
• On February 2, 2024, Milestone Scientific entered into an agreement to sell its unused NOLs and R&D tax credits to Comcast Corporation.
• The company received a net amount of $1,983,095 from Comcast Corporation on April 8, 2024.
• These funds will be used for general corporate purposes and working capital, specifically for allowable expenses under the Program.
• Milestone Scientific is required to maintain its headquarters or base of operations in New Jersey for five years following the closing date.
• The company must also submit quarterly reports to the State of New Jersey for five years.
• The funds are subject to recapture up to the face value of the sold tax credits if the company breaches its obligations under the Program.

Sentiment

Score: 7

Explanation: The document reflects a positive development for the company, securing non-dilutive funding. However, there are obligations and risks associated with the program.

Positives

• Milestone Scientific successfully monetized its unused tax benefits, generating $1,983,095 in cash.
• The funds will be used for general corporate purposes and working capital, strengthening the company's financial position.
• The agreement provides a non-dilutive source of funding.

Negatives

• The funds are subject to recapture if Milestone Scientific fails to maintain its New Jersey headquarters or use the funds for allowable expenses.
• The company is obligated to provide quarterly reports to the State of New Jersey for five years, adding an administrative burden.

Risks

• There is a risk of fund recapture if Milestone Scientific breaches its obligations under the New Jersey program.
• The company must maintain its New Jersey headquarters for five years, which could limit flexibility.

Future Outlook

The company intends to use the funds for general corporate purposes and working capital, specifically for allowable expenses under the Program.

Management Comments

• The company has agreed to maintain its headquarters or base of operations in New Jersey for five years following the closing date.
• The company must make quarterly reports to the State of New Jersey for five years.

Industry Context

This transaction is an example of how companies can leverage government programs to monetize tax benefits and secure non-dilutive funding, which is common in the biotechnology and technology sectors.

Comparison to Industry Standards

• Many emerging technology and biotechnology companies utilize similar state programs to monetize tax benefits.
• The sale of NOLs and R&D tax credits is a common practice for companies with limited taxable income.
• The amount received is typical for a company of this size and stage in the New Jersey program.

Stakeholder Impact

• Shareholders will benefit from the additional funding, which can support the company's operations and growth.
• Employees may benefit from the improved financial stability of the company.
• The company's continued presence in New Jersey will benefit the local economy.

Next Steps

• Milestone Scientific will use the funds for general corporate purposes and working capital.
• The company will maintain its New Jersey headquarters for five years.
• The company will submit quarterly reports to the State of New Jersey for five years.

Key Dates

Keywords

tax credits, NOL, Net Operating Loss, R&D, Research and Development, New Jersey, funding, Comcast, Milestone Scientific, financial assistance